Connection

THOMAS MONATH to Adult

This is a "connection" page, showing publications THOMAS MONATH has written about Adult.
Connection Strength

0.484
  1. A multitope SARS-CoV-2 vaccine provides long-lasting B cell and T cell immunity against Delta and Omicron variants. J Clin Invest. 2022 05 16; 132(10).
    View in: PubMed
    Score: 0.047
  2. Clinical development of a recombinant Ebola vaccine in the midst of an unprecedented epidemic. Vaccine. 2017 08 16; 35(35 Pt A):4465-4469.
    View in: PubMed
    Score: 0.034
  3. Yellow fever vaccine seroconversion in travelers. Am J Trop Med Hyg. 2011 Oct; 85(4):748-9.
    View in: PubMed
    Score: 0.023
  4. An inactivated cell-culture vaccine against yellow fever. N Engl J Med. 2011 Apr 07; 364(14):1326-33.
    View in: PubMed
    Score: 0.022
  5. Suspected yellow fever vaccine-associated viscerotropic adverse events (1973 and 1978), United States. Am J Trop Med Hyg. 2010 May; 82(5):919-21.
    View in: PubMed
    Score: 0.020
  6. Comparison of the safety and immunogenicity of ACAM1000, ACAM2000 and Dryvax in healthy vaccinia-naive adults. Vaccine. 2009 Mar 04; 27(10):1637-44.
    View in: PubMed
    Score: 0.019
  7. Possible autoimmune reactions following smallpox vaccination: the biologic false positive test for syphilis. Vaccine. 2009 Mar 04; 27(10):1645-50.
    View in: PubMed
    Score: 0.019
  8. A live, attenuated recombinant West Nile virus vaccine. Proc Natl Acad Sci U S A. 2006 Apr 25; 103(17):6694-9.
    View in: PubMed
    Score: 0.015
  9. Lack of transmission of vaccinia virus. Emerg Infect Dis. 2006 Apr; 12(4):698-700.
    View in: PubMed
    Score: 0.015
  10. Live attenuated chimeric yellow fever dengue type 2 (ChimeriVax-DEN2) vaccine: Phase I clinical trial for safety and immunogenicity: effect of yellow fever pre-immunity in induction of cross neutralizing antibody responses to all 4 dengue serotypes. Hum Vaccin. 2006 Mar-Apr; 2(2):60-7.
    View in: PubMed
    Score: 0.015
  11. Yellow fever 17D vaccine safety and immunogenicity in the elderly. Hum Vaccin. 2005 Sep-Oct; 1(5):207-14.
    View in: PubMed
    Score: 0.015
  12. A novel, cell culture-derived smallpox vaccine in vaccinia-naive adults. Vaccine. 2005 May 09; 23(25):3301-9.
    View in: PubMed
    Score: 0.015
  13. Challenge model for Helicobacter pylori infection in human volunteers. Gut. 2004 Sep; 53(9):1235-43.
    View in: PubMed
    Score: 0.014
  14. Evaluation of humoral immune response after yellow fever infection: an observational study on patients from the 2017-2018 sylvatic outbreak in Brazil. Microbiol Spectr. 2024 May 02; 12(5):e0370323.
    View in: PubMed
    Score: 0.013
  15. Yellow fever vaccine. Recommendations of the Advisory Committee on Immunization Practices (ACIP), 2002. MMWR Recomm Rep. 2002 Nov 08; 51(RR-17):1-11; quiz CE1-4.
    View in: PubMed
    Score: 0.012
  16. A Randomized Dose-Escalating Phase I Trial of a Replication-Deficient Lymphocytic Choriomeningitis Virus Vector-Based Vaccine Against Human Cytomegalovirus. J Infect Dis. 2022 04 19; 225(8):1399-1410.
    View in: PubMed
    Score: 0.012
  17. Clinical proof of principle for ChimeriVax: recombinant live, attenuated vaccines against flavivirus infections. Vaccine. 2002 Jan 15; 20(7-8):1004-18.
    View in: PubMed
    Score: 0.012
  18. Transcriptomic signatures induced by the Ebola virus vaccine rVSV?G-ZEBOV-GP in adult cohorts in Europe, Africa, and North America: a molecular biomarker study. Lancet Microbe. 2022 02; 3(2):e113-e123.
    View in: PubMed
    Score: 0.011
  19. Safety and immunogenicity of increasing doses of a Clostridium difficile toxoid vaccine administered to healthy adults. Infect Immun. 2001 Feb; 69(2):988-95.
    View in: PubMed
    Score: 0.011
  20. Immunogenicity and safety of fractional doses of yellow fever vaccines: a randomised, double-blind, non-inferiority trial. Lancet. 2021 01 09; 397(10269):119-127.
    View in: PubMed
    Score: 0.011
  21. Determinants of antibody persistence across doses and continents after single-dose rVSV-ZEBOV vaccination for Ebola virus disease: an observational cohort study. Lancet Infect Dis. 2018 07; 18(7):738-748.
    View in: PubMed
    Score: 0.009
  22. Vaccine development against infection with Helicobacter pylori. Br Med Bull. 1998; 54(1):229-41.
    View in: PubMed
    Score: 0.009
  23. Phase 2 Placebo-Controlled Trial of Two Vaccines to Prevent Ebola in Liberia. N Engl J Med. 2017 10 12; 377(15):1438-1447.
    View in: PubMed
    Score: 0.009
  24. Assessing the safety and immunogenicity of recombinant vesicular stomatitis virus Ebola vaccine in healthy adults: a randomized clinical trial. CMAJ. 2017 Jun 19; 189(24):E819-E827.
    View in: PubMed
    Score: 0.008
  25. Safety and immunogenicity of the rVSV?G-ZEBOV-GP Ebola virus vaccine candidate in healthy adults: a phase 1b randomised, multicentre, double-blind, placebo-controlled, dose-response study. Lancet Infect Dis. 2017 08; 17(8):854-866.
    View in: PubMed
    Score: 0.008
  26. A Recombinant Vesicular Stomatitis Virus Ebola Vaccine. N Engl J Med. 2017 01 26; 376(4):330-341.
    View in: PubMed
    Score: 0.007
  27. Should yellow fever vaccine be included in the expanded program of immunization in Africa? A cost-effectiveness analysis for Nigeria. Am J Trop Med Hyg. 1993 Feb; 48(2):274-99.
    View in: PubMed
    Score: 0.006
  28. Viscerotropic disease following yellow fever vaccination in Peru. Vaccine. 2009 Oct 09; 27(43):5974-81.
    View in: PubMed
    Score: 0.005
  29. Clostridium difficile toxoid vaccine in recurrent C. difficile-associated diarrhea. Gastroenterology. 2005 Mar; 128(3):764-70.
    View in: PubMed
    Score: 0.004
  30. Exercise-induced serum enzyme elevations confounding the evaluation of investigational drug toxicity. Report of two cases in a vaccine trial. Hum Vaccin. 2005 Jan-Feb; 1(1):24-9.
    View in: PubMed
    Score: 0.004
  31. High rates of recurrence and of transient reinfections of Helicobacter pylori in a population with high prevalence of infection. Am J Gastroenterol. 2003 Nov; 98(11):2395-402.
    View in: PubMed
    Score: 0.003
  32. Helicobacter pylori reinfection is common in Peruvian adults after antibiotic eradication therapy. J Infect Dis. 2003 Nov 01; 188(9):1263-75.
    View in: PubMed
    Score: 0.003
  33. Clostridium difficile vaccine and serum immunoglobulin G antibody response to toxin A. Infect Immun. 2003 Mar; 71(3):1608-10.
    View in: PubMed
    Score: 0.003
  34. Safety and efficacy of low dose Escherichia coli enterotoxin adjuvant for urease based oral immunisation against Helicobacter pylori in healthy volunteers. Gut. 2002 Nov; 51(5):634-40.
    View in: PubMed
    Score: 0.003
  35. Serious adverse events associated with yellow fever 17DD vaccine in Brazil: a report of two cases. Lancet. 2001 Jul 14; 358(9276):91-7.
    View in: PubMed
    Score: 0.003
  36. Posttreatment follow-up of Helicobacter pylori infection using a stool antigen immunoassay. Clin Diagn Lab Immunol. 2001 Jul; 8(4):718-23.
    View in: PubMed
    Score: 0.003
  37. St Louis encephalitis. Quantitative histologic and immunofluorescent studies. Arch Neurol. 1981 Jun; 38(6):329-34.
    View in: PubMed
    Score: 0.003
  38. Yellow fever in the Gambia, 1978--1979: epidemiologic aspects with observations on the occurrence of orungo virus infections. Am J Trop Med Hyg. 1980 Sep; 29(5):912-28.
    View in: PubMed
    Score: 0.003
  39. Oral immunization with urease and Escherichia coli heat-labile enterotoxin is safe and immunogenic in Helicobacter pylori-infected adults. Gastroenterology. 1999 Apr; 116(4):804-12.
    View in: PubMed
    Score: 0.002
  40. Serologic IgG response to urease in Helicobacter pylori-infected persons from Mexico. Am J Trop Med Hyg. 1999 Apr; 60(4):587-92.
    View in: PubMed
    Score: 0.002
  41. Risk of Helicobacter pylori infection among long-term residents in developing countries. Am J Trop Med Hyg. 1999 Feb; 60(2):267-70.
    View in: PubMed
    Score: 0.002
  42. St. Louis encephalitis in Memphis-Shelby County, Tennessee, 1975: epidemiologic aspects of human cases. South Med J. 1978 Jun; 71(6):633-7.
    View in: PubMed
    Score: 0.002
  43. Lymphocytic 2',5'-oligoadenylate synthetase activity increases prior to the appearance of neutralizing antibodies and immunoglobulin M and immunoglobulin G antibodies after primary and secondary immunization with yellow fever vaccine. Clin Diagn Lab Immunol. 1995 May; 2(3):302-6.
    View in: PubMed
    Score: 0.002
  44. Lassa fever: review of epidemiology and epizootiology. Bull World Health Organ. 1975; 52(4-6):577-92.
    View in: PubMed
    Score: 0.002
  45. Lassa fever in the Eastern Province of Sierra Leone, 1970-1972. II. Clinical observations and virological studies on selected hospital cases. Am J Trop Med Hyg. 1974 Nov; 23(6):1140-9.
    View in: PubMed
    Score: 0.002
  46. A hospital epidemic of Lassa fever in Zorzor, Liberia, March-April 1972. Am J Trop Med Hyg. 1973 Nov; 22(6):773-9.
    View in: PubMed
    Score: 0.002
  47. Clinical presentation of Lassa fever cases during the hospital epidemic at Zorzor, Liberia, March-April 1972. Am J Trop Med Hyg. 1973 Nov; 22(6):780-4.
    View in: PubMed
    Score: 0.002
  48. Yellow fever vaccination and pregnancy: a four-year prospective study. Trans R Soc Trop Med Hyg. 1993 May-Jun; 87(3):337-9.
    View in: PubMed
    Score: 0.002
  49. The 1970 yellow fever epidemic in Okwoga District, Benue Plateau State, Nigeria. I. Epidemiological observations. Bull World Health Organ. 1973; 49(2):113-21.
    View in: PubMed
    Score: 0.002
  50. The 1970 yellow fever epidemic in Okwoga District Benue Plateau State, Nigeria. 2. Immunity survey to determine geographic limits and origins of the epidemic. Bull World Health Organ. 1973; 49(2):123-8.
    View in: PubMed
    Score: 0.002
  51. The 1970 yellow fever epidemic in Okwoga District, Benue Plateau State, Nigeria. 3. Serological responses in persons with and without pre-existing heterologous group B immunity. Bull World Health Organ. 1973; 49(3):235-44.
    View in: PubMed
    Score: 0.002
  52. Neutralizing antibody responses in the major immunoglobulin classes to yellow fever 17D vaccination of humans. Am J Epidemiol. 1971 Feb; 93(2):122-9.
    View in: PubMed
    Score: 0.001
  53. Studies on California encephalitis in Minnesota. Am J Epidemiol. 1970 Jul; 92(1):40-50.
    View in: PubMed
    Score: 0.001
  54. Epidemic yellow fever caused by an incompetent mosquito vector. Trop Med Parasitol. 1989 Dec; 40(4):396-9.
    View in: PubMed
    Score: 0.001
  55. Urban yellow fever epidemic in western Nigeria, 1987. Trans R Soc Trop Med Hyg. 1989 May-Jun; 83(3):401-6.
    View in: PubMed
    Score: 0.001
  56. Human immunodeficiency virus infection in a rural community. J Fla Med Assoc. 1988 May; 75(5):301-4.
    View in: PubMed
    Score: 0.001
  57. Epidemic yellow fever in eastern Nigeria, 1986. Lancet. 1988 Mar 19; 1(8586):630-3.
    View in: PubMed
    Score: 0.001
  58. The effect of immune globulin on the response to trivalent oral poliovirus and yellow fever vaccinations. Bull World Health Organ. 1984; 62(4):585-90.
    View in: PubMed
    Score: 0.001
  59. Reported encephalitis associated with California serogroup virus infections in the United States, 1963-1981. Prog Clin Biol Res. 1983; 123:31-41.
    View in: PubMed
    Score: 0.001
  60. Human arboviral infections in the United States in 1980. J Infect Dis. 1982 Feb; 145(2):283-6.
    View in: PubMed
    Score: 0.001
  61. Arbovirus infections among laboratory personnel in Ibadan, Nigeria. Am J Trop Med Hyg. 1981 Jul; 30(4):855-61.
    View in: PubMed
    Score: 0.001
  62. St Louis encephalitis in Ohio, September 1975: clinical and EEG studies in 16 cases. Arch Intern Med. 1979 May; 139(5):561-6.
    View in: PubMed
    Score: 0.001
  63. Epidemiologic investigations of the 1969 epidemic of Venezuelan encephalitis in Ecuador. Am J Epidemiol. 1975 Nov; 102(5):400-13.
    View in: PubMed
    Score: 0.000
  64. Lassa fever in the Eastern Province of Sierra Leone, 1970-1972. I. Epidemiologic studies. Am J Trop Med Hyg. 1974 Nov; 23(6):1131-9.
    View in: PubMed
    Score: 0.000
  65. Bwamba virus infection: a sero-survey of veterbrates in five ecological zones in Nigeria. Trans R Soc Trop Med Hyg. 1974; 68(6):461-5.
    View in: PubMed
    Score: 0.000
  66. Lassa fever in Britain: an imported case. Br Med J. 1973 Sep 22; 3(5881):616-7.
    View in: PubMed
    Score: 0.000
  67. Studies on Tataguine infection in Nigeria. Trop Geogr Med. 1972 Sep; 24(3):298-302.
    View in: PubMed
    Score: 0.000
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.